TAK-411
Phase 2Biologic
TakedaTAK-411 is one of 13 biologic programs targeting Chronic Inflammatory Demyelinating Polyradiculoneuropathy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
#DrugCompanyPhaseTrials
1Campath
GGenzyme, a Sanofi Company
Approved
Gilenya
NovartisPhase 3
Rituxan
RochePhase 3
Rysodeg
UCBPhase 2
Fabhalta
Johnson & JohnsonPhase 2
HYQVIA
TakedaPhase 3
Avonex
EMD SeronoPhase 2
Immunoglobulin
SanofiPhase 2
TAK-771
TakedaPhase 3
TAK-881
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TAK-411. EMBL-EBI & Wellcome Sanger Institute.
- [4]